Moshe Ornstein MD
@MosheOrnsteinMD
GU oncologist at Cleveland Clinic. Views/Tweets/RTs are my own & not medical advice. Author of Cancer in Halachah: https://shorturl.at/iMO38
Thrilled – Thanks God – to finally bring this to the finish line. “Cancer in Halachah” covers the medical and halachic (Jewish law/ethics) considerations of cancer screening and treatment. Full of practical advice and suggestions for patients. israelbookshoppublications.com/store/pc/Cance…
We’re proud to present the KidneyCAN Catalyst Award to Dr. Rana McKay of UC San Diego. Dr. McKay is a leader whose work has helped move the field of kidney cancer forward through groundbreaking research, clinical collaboration, and a deep commitment to patients and advocacy. Her…
Congratulation to Dr. Marston Linehan on receiving the inaugural Kidney Cancer Hall of Fame award from @kidneycan at #KCRS25. A mentor to many of us and an inspiration to all in the kidney cancer community.
Great line up for trials in progress kicked off by @NazliDizman on ivonescimab (bispecific anti PD-1 and VEGF) in RCC @kidneycan #KCRS25
Passionate discussion at #KCRS25 about the mission that drives @kidneycan And, frankly, a disgraceful lack of funding for KCRP this year.
✅ Success is possible even in rare cancer subtypes 🌟 🤝 Patient-centered care 🗣️ Advocacy @KidneyCAN 🧬 Tissue-agnostic biomarkers 🧪 Innovative trial designs 🏭 Industry support 📊 Prospective randomized phase 3 data wherever possible Great panel at #KCRS25 with optimism…
Dr. Henske #KCRS25 providing important updates on chromophobe RCC. Interesting data regarding KIT as a potential target with early phase ongoing trials. @kidneycan
@BradMcG04 concluding thoughts on papillary RCC. Glad to have IO/TKI options now in this setting and curious to see what upcoming trials reveal. #kcrs25 @kidneycan
pre meeting session at #KCRS25 on Variant Kidney Cancers @kidneycan
The KCRS 2025 Abstract Book is now live! Explore cutting-edge #KidneyCancer research from investigators across the globe. We’re proud to showcase the work that’s driving real progress for patients and families. Check it out! kcrs.kidneycan.org #KCRS25 #AcceleratingCures
Hot off the presses! Tips from the editorial board @JCO_ASCO @ASCO on what we're looking for in narrative medicine or poetry pieces for the Journal of Clinical Oncology! The Art of the Art of Oncology | @DrSGraff @SylvesterCancer @UMiamiHealth ascopubs.org/doi/10.1200/JC…
Just three days until KCRS 2025! We’re getting ready to welcome researchers, clinicians, advocates, and patients from around the world to explore the future of #KidneyCancer research. #KCRS25 #AcceleratingCures
Ab#4516 @ASCO #ASCO25 by @TiansterZhang 👉bit.ly/4k7p5Wv👉@ALLIANCE_org Ph 3 PDIGREE trial 👉 ipi-nivo induction (f/ued by nivo, cabo or nivo-cabo in mccRCC #kidneycancer 👉Initial outcomes with induction ipi-nivo👇@DrChoueiri @OncoAlert @urotoday @KidneyCAN
Special thanks to clinical research teams at our site @CleClinicMD & all sites 🌏 for their diligence in ensuring compliance with PROs & data entry. @AmandaNizamMD @ChrisWeeMD @MosheOrnsteinMD @TimGilliganMD @caseccc
🌟How to Optimize Patient Selection in Perioperative RCC Therapy🌟 Insights from Guillermo de Velasco #IKCSEU2025 @KidneyCancer @OncoAlert @GUOncologyNow @UroToday 🟠 Neoadjuvant: may downstage, treat micromets, ↑compliance 🟠 Adjuvant: DFS/OS benefit in selected pts (KN-564),…
Hot panel discussion about #ICPI and kidney toxicity #CCNephupdate25 @CleClinicKidney @AliMehdiMD @cavanaugh_do @MosheOrnsteinMD
From Challenges to Cures: Improving Outcomes in Patients With Renal Cell Carcinoma | JCO Oncology Practice ascopubs.org/doi/10.1200/OP…
1/7 🚨 Newly published @JAMAOnc! Deep dive into strategies for RCC patients progressing on ICIs 🚨 A comprehensive review on the latest data and emerging approaches. Read here: 🧵👇jamanetwork.com/journals/jamao… #RCC #Immunotherapy #JAMAOncology
Long waited review on Recent Developments in the management of Renal Cell Cancer by @DrRanaMcKay @JCOOP_ASCO @OncoAlert ascopubs.org/doi/pdf/10.120…
Can treatment breaks improve outcomes for patients with metastatic renal cell carcinoma? @MosheOrnsteinMD discusses the evolution of mRCC therapies & intermittent treatment on this week’s episode of the @CleClinicMD Cancer Advances podcast #CleClinicCancer cle.clinic/40XwsYv
These are the 2 key slides from the #Talapro2 presentation @asco #GU25 Where HR crosses 1.0 in pts w/no known HRR mutation status & Gd3 toxicity difference of 75% vs 45% I think there is still much to discussion to be had of value of #PARP +#ARPI in unselected #ProstateCancer